NCT05457933View on ClinicalTrials.gov

Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

July 29, 2022

Primary Completion Date

January 14, 2023

Study Completion Date

January 14, 2023

Conditions
Type2diabetesCoronary Artery Disease
Interventions
DRUG

Dapagliflozin

Dapagliflozin 10 mg, every day before breakfast. Glargine insulin 300 Units/mL, average dose: 10-20 U/day; Insulin lispro 100 Units/mL, average dose: 10-30 U/day

DRUG

Glargine

Glargine insulin; 300 Units/mL, average dose: 10-20 U/day, Insulin lispro 100 Units/mL, average dose: 10-30 U/day

Trial Locations (1)

122001

Division Of Endocrinology and Diabetes, Medanta The Medicity, Gurgaon

All Listed Sponsors
lead

Medanta, The Medicity, India

OTHER